Abstract
Background Sub-Saharan Africa bears the world’s highest incidence of cervical cancer. To address the lack of widespread screening and treatment that contributes to this burden, the World Health Organization (WHO) recommends that low-resource countries adopt simplified protocols for screening directly coupled with treatment. The WHO recommendations present an opportunity — akin to what has been done for HIV care in Africa — for a true public health approach to cervical cancer control in resource-poor settings. We evaluated the feasibility of such a public health approach to cervical cancer that features community-based self-administered HPV screening and mobile treatment provision.
Methods In two rural districts of western Uganda, we first trained Village Health Team members (VHTs, also known as Community Health Workers) in a one-day session in the fundamental aspects of cervical cancer and its prevention. We then provided guidance to the VHTs to mobilize adult women from different communities within the district to attend a one-day HPV screening fair at a central location in their respective community. On the day of the fair, the study team and VHTs provided educational talks and instructions for self-collection of a vaginal sample. The samples were subsequently tested for high risk HPV (hrHPV) E6/E7 mRNA using the APTIMA® platform. Women who tested positive for hrHPV were re-contacted and referred for treatment with cryotherapy at a mobile treatment unit in their community. Visual assessment with acetic acid was used to guide suitability for cryotherapy in the mobile treatment unit versus further referral to a larger facility for a loop electrosurgical excision procedure (LEEP).
Results Between March and November 2016, 2,142 women attended a health fair in one of 24 communities in rural Western Uganda and expressed interest in being screened for cervical cancer; 1902 were eligible for cervical cancer screening of which 1,892 (99.5%) provided a self-collected vaginal sample. The median age of those screened was 34 years (IQR: 28-40), HIV prevalence was 11%, and most (95%) had not been previously screened. Almost all women stated that they would perform the self-collection again and recommend it to a friend. Prevalence of any hrHPV mRNA was 21% (HPV-16, 6%; HPV-18/45, 1.9%). Among the 393 women with detectable hrHPV mRNA, 89% had their results transmitted to them, of whom 86% returned to the mobile treatment unit. At the mobile treatment, 85% of women underwent ablative therapy, with the remainder deferred either because of pregnancy (9.0%), need for LEEP (2.6%) or other reasons (3.3%).
Conclusion A public health approach to cervical cancer screening, featuring community-based self-administered HPV testing and mobile treatment, was feasible and readily accepted by community women. The process is termed a “public health approach” because — as is the case for HIV care in the region — it explicitly concedes perfection at the individual level in deference to reaching a larger fraction of the population. The findings support further optimization and evaluation of this approach as a means of scaling up cervical cancer control in low resource settings. If resources for cancer control remain limited in sub-Saharan Africa, this public approach may offer one of the most efficient solutions for stemming the incessant tide of cervical cancer in the region.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Institutes of Health (U54 CA190153 and P30 AI027763).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available on request from the authors
Abbreviations
- CI
- confidence interval
- DAG
- directed acyclic graph
- HIV
- human immunodeficiency virus
- HPV
- human papillomavirus
- hrHPV
- high-risk human papillomavirus
- IQR
- interquartile range
- mRNA
- messenger ribonucleic acid
- VHTs
- Village Health Team members
- WHO
- World Health Organisation